TBX1 and metastatic neoplasm: The QuEST1 study showed that the triple-hit approach of BNVax (a therapeutic poxviral vaccine targeting brachyury), anti-PD-L1 monoclonal antibodies, and interleukin-15 superagonist complexes have eradicated traces of bone detectability of bony metastasis in two patients with metastatic disease [69].